Chronic Kidney Disease

Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.

Our February 2024 month in review spotlights news in IgAN identification and management as well as recent research about various factors impacting renal care outcomes in different patient populations.

Nearly 30% of patients were receiving potentially inappropriately prescribed medications at the start of the study and more than 20% were still receiving these medications 1 year later.

Our January 2024 month-in-review spotlights some of our top coverage in nephrology, ranging from FDA news to clinical trial data and research about approaches to improving renal health.

Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.

Low eGFRcr-cys was more strongly and uniformly associated with adverse outcomes compared to low eGFRcr in an older patient population, highlighting the benefit of including cystatin C in GFR estimation.

Results showed treatment with dapagliflozin 10 mg was associated with clinically meaningful attenuations in eGFR slope in patients with CKD and urinary albumin-to-creatinine ratio < 200 mg/g.

Use of the electronic AKI alert system led to slight improvements in intervention rates and AKI diagnosis, although kidney function and patient-centered outcomes did not differ from patients receiving usual care.

Patients on maintenance hemodialysis classified as having a high erythropoietin resistance index had a greater risk of all-cause mortality.

On January 19, 2024, the FDA announced the addition of a Boxed Warning to the labeling of denosumab (Prolia), citing evidence of an increased risk of severe hypocalcemia in patients with chronic kidney disease.

Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.

Investigators observed no change in Insomnia Severity Index scores from baseline to weeks 7 and 25 with CBT-1, trazodone, or placebo, suggesting these insomnia treatment options are not effective for patients undergoing hemodialysis.

Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.

A new study is raising awareness around the effects of structural racism on the prevalence of chronic health conditions.

Thyroid dysfunction was greater among patients with more severe CKD coupled with a high urine protein level.

These results highlight the potential of preventing increasing CKD burden and of preventing subsequent cardiovascular conditions, especially given current rates of obesity among adolescents.

Patients who reported almost daily fresh vegetable consumption had higher eGFR compared to those with occasional consumption and those who consumed salt-preserved vegetables.

These data helped to verify the MDRD-4 and CKD-EPI equations’ accuracy in the estimation of GFR among the Brazilian population.

A new study demonstrated hemoglobin levels significantly increased with ziltivekimab, showing the monoclonal antibody has the potential to serve as a new treatment method for anemia.

Data from a 24-week, prospective trial conducted at a hospital in China provide insight into the effects of roxadustat on iron metabolism relative to use of ESAs in patients using peritoneal dialysis.

At ASN Kidney Week 2023, we collected perspectives from 10 key opinion leaders in nephrology on what they see as the most significant news in their specialty from the past year.

Dhiren Patel, PharmD, and Bob Busch, MD, interview Fatima Cody Stanford, MD, MPH, MPA, an obesity medicine specialist, to examine the cardiovascular (CV) impact of obesity and delve into the potential benefits of newer weight loss medications in mitigating CV risk and heart failure.

Patrick Rossignol, MD, PhD, provides additional perspective on the results of the ALCHEMIST trial from Kidney Week 2023.

Analysis of nearly 15k patients with non-dialysis-dependent CKD and anemia provides insight into contemporary trends in management.

Preliminary data from the open-label RUBY-3 trial were presented at the American Society of Nephrology Kidney Week 2023.

Results of the ZENITH-CKD trial provide evidence of the safety and efficacy profile of combination zibotentan plus dapagliflozin in patients with chronic kidney disease.

Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.

An analysis of Target-HTN provides new insight into the effects of lorundrostat among patients with uncontrolled or treatment-resistant hypertension.

Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.

John W. Ostrominski, MD, describes the prevalence and overlap of cardiac, renal, and metabolic conditions in US adults over a 20-year period.